As such, the Rho/ROCK signalling pathway has emerged as a promising druggable target to treat GON because one of the major causative factors of blindness in glaucoma is recognized to arise from perturbed perfusion at the level of optic nerve head50, 51, 52. This evidence concerns the gene RHO and blindness (disorder).